Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Yisheng Biopharma
company
About
Yisheng Biopharma is a global, fully integrated bio-pharmaceutical company.
- 501 - 1000
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $130M
- Industries
- Biopharma,Biotechnology,Health Care
- Founded date
- Jan 1, 2002
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$130M
Yisheng Biopharma has raised a total of
$130M
in funding over 2 rounds. Their latest funding was raised on
Feb 24, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 24, 2021 | Series B | $130M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Yisheng Biopharma is funded by 1 investors.
Superstring Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
